Your session is about to expire
← Back to Search
Pancreatic Cancer Early Detection Consortium (PRECEDE Trial)
N/A
Recruiting
Research Sponsored by Arbor Research Collaborative for Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 years
Awards & highlights
No Placebo-Only Group
Summary
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Eligible Conditions
- Pancreatic Cancer
- Pancreatic Cysts
- Genetic Predisposition
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 6 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Development of PDAC
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Arbor Research Collaborative for HealthLead Sponsor
20 Previous Clinical Trials
25,467 Total Patients Enrolled
Diane Simeone, MDStudy ChairUC San Diego Moores Cancer Center